Peptide Comparison
Testagen vs Pancragen
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Testagen and Pancragen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). On the catalogued data layer Testagen has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Testagen's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Testagen | Pancragen | |
|---|---|---|
| Class | Khavinson short peptide bioregulator | Khavinson short peptide bioregulator |
| Drug class | Longevity | Metabolic & Weight |
| Mechanism | Tissue-specific gene expression in testicular cells | Tissue-specific gene expression in pancreatic beta-cells |
| Route | Oral | Oral |
| Half-life | Short (minutes) | Short (minutes) |
| Dosage (research) | Oral capsule 1-2x daily | Oral capsule 1-2x daily |
| Evidence tier | Russian Research | Russian Research |
| Research depth | 5 indexed | 8 indexed |
| Availability | Research | Research |
| Reported risks | Limited Western evidence | Sparse controlled trials |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Testagen or Pancragen?
Testagen and Pancragen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). On the catalogued data layer Testagen has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Testagen's evidence base is currently denser.
What is the difference between Testagen and Pancragen?
Testagen is classed as Khavinson short peptide bioregulator; Pancragen is classed as Khavinson short peptide bioregulator. Reported mechanism: Testagen, Tissue-specific gene expression in testicular cells; Pancragen, Tissue-specific gene expression in pancreatic beta-cells. Reported half-life: Testagen, Short (minutes); Pancragen, Short (minutes). Routes in published studies: Testagen, Oral; Pancragen, Oral.
Which has stronger evidence, Testagen or Pancragen?
Testagen and Pancragen sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Testagen is graded Russian Research, with 3 cited sources on its reference page and 5 indexed studies. Pancragen is graded Russian Research, with 2 cited sources on its reference page and 8 indexed studies.
Which is more accessible, Testagen or Pancragen?
Neither Testagen nor Pancragen is an FDA-approved drug. Catalog status: Testagen, Research; Pancragen, Research.
Are Testagen and Pancragen ever combined?
Testagen and Pancragen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…